Skip to main content
OpenTrials
Completed

NCT Number: NCT03527277

Orange Juice And Sugar Intervention Study

The objectives of this proposal are to address the gaps in knowledge regarding the metabolic effects of consuming orange juice, the most frequently consumed fruit juice in this country, compared to sugar-sweetened beverage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, Davis

Davis, California, 95616, United States

About this study

Specific Aims: There is considerable epidemiological evidence that demonstrates associations between added sugar/sugar-sweetened beverage consumption and increased risk for or prevalence of chronic diseases such as cardiovascular disease (CVD), type 2 diabetes (T2D), metabolic syndrome, and gout. Especially concerning is recent evidence from National Health and Nutrition Examination Survey III that demonstrates that there is increased risk of CVD mortality with increased intake of added sugar across quintiles (Yang, 2014). Even the US mean added sugar intake, 15% of daily calories, was associated with an 18% increase in risk of CVD mortality over 15 years. The results from the investigator's recently completed study (1R01 HL09133) corroborate these findings (Stanhope, 2015). They demonstrate that supplementing the ad libitum diets of young adults with beverages containing 0, 10, 17.5 or 25% of daily energy requirement (Ereq) as high fructose corn syrup (HFCS) affects lipid/lipoprotein risk factors for CVD in a dose response manner. Specifically, levels of nonHDL-cholesterol(C), LDL-C, apolipoprotein B (apoB), and postprandial triglycerides (TG) increased linearly over a 2-week period with increasing doses of HFCS. Furthermore, even the participants consuming the 10% Ereq dose exhibited increased levels of these risk factors compared to baseline.

These and similar results have helped to lead to reductions in soda consumption in this country, and new dietary guidelines and FDA food labeling requirements to promote reductions in added sugar consumption. However, there are gaps in knowledge about other sugar-containing foods that lead to public confusion concerning healthier options for soda, and impede further progress in implementing public health policies that will promote further reductions in soda consumption. One such food is naturally-sweetened fruit juice. The amount of sugar in fruit juice is comparable to the amount in soda. Because of this, a consumer seeking answers on the internet will find many articles in which experts state or suggest that the effects of consuming fruit juice are as detrimental as or even worse than those of soda. However, in contrast to soda, fruit juice contains micronutrients and bioactives that may promote health. Therefore the consumer can also find numerous articles on the internet where the health benefits of fruit juice and these bioactives are extolled. There are a limited number of clinical dietary intervention studies that have directly compared the metabolic effects of consuming fruit juice and sugar-sweetened beverage, and their results are not conclusive. Thus we will pursue the following Specific Aims:

  • Specific Aim 1: To compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages for 4 weeks on risk factors for CVD and other chronic disease in normal weight and overweight men and women.
  • Specific Aim 2: To mechanistically compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages on metabolic processes associated with the development of CVD and T2D in normal weight and overweight men and women.
  • Specific Aim 3: To relate the changes assessed under Specific Aims 1 and 2 to the changes in the urinary levels of metabolites and catabolites of the main flavanones in orange juice, hesperetin and naringenin.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

men and pre-menopausal women Body mass index: 20-35 kg/m2 Body weight > than 50 kg Self-reported stable body weight during the prior six months

Exclusion criteria

Fasting glucose >125 mg/dl Evidence of liver disorder (AST or ALT >200% upper limit of normal range) Evidence of kidney disorder (>2.0 mg/dl creatinine) Evidence of thyroid disorder (out of normal range) Systolic blood pressure consistently over 140 mmHg or diastolic blood pressure over 90 mmHg Triglycerides > 400 mg/dl LDL-C > 160 mg/dl in combination with Chol:HDL > 4 Hemoglobin < 10 g/dL Pregnant or lactating women Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents.

Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results Use of tobacco Strenuous exerciser (>3.5 hours/week at a level more vigorous than walking) Surgery for weight loss Diet exclusions: Food allergies, special dietary restrictions, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu Veins that are assessed by the R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter.

Pre-existing claustrophobia or metal implants that preclude magnetic resonance imaging Any other condition that, in the opinion of the investigators, would put the subject at risk

-

Treatment and study plan

Naturally-sweetened orange juice

Other

Commercially-available ready-to-serve refrigerated orange juice

Sugar-sweetened beverage

Other

Sugar-sweetened water flavored with Kool-Aid (TM)

Primary outcomes

  1. Fasting Low Density Lipoprotein Cholesterol (LDL-C)

    Time frame: 4 weeks

    Absolute change of plasma LDL-C concentration (4 week value - 0 week value)

  2. Postprandial Low Density Lipoprotein Cholesterol (LDL-C)

    Time frame: 4 weeks

    Absolute change of plasma postprandial LDL-C concentration (4 week value - 0 week value)

  3. Fasting Apolipoprotein B (apoB)

    Time frame: 4 weeks

    Absolute change of plasma apoB concentration (4 week value - 0 week value)

  4. Postprandial Apolipoprotein B (apoB)

    Time frame: 4 weeks

    Absolute change of plasma postprandial apoB concentration (4 week value - 0 week value)

  5. Fasting Uric Acid

    Time frame: 4 weeks

    Absolute change of plasma uric acid concentration (4 week value - 0 week value)

  6. Postprandial Uric Acid

    Time frame: 4 weeks

    Absolute change of post-dinner 4-hour AUC plasma uric acid concentration (4 week value - 0 week value)

  7. Fasting Apolipoprotein CIII (apoCIII)

    Time frame: 4 weeks

    Absolute change of fasting plasma apoCIII concentration (4 week value - 0 week value)

  8. Postprandial Apolipoprotein CIII (apoCIII)

    Time frame: 4 weeks

    Absolute change of plasma postprandial apoCIII concentration (4 week value - 0 week value)

  9. Postprandial Triglyceride

    Time frame: 4 weeks

    Absolute change of 4-h post-dinner AUC plasma triglyceride concentration (4 week value - 0 week value)

  10. Hepatic Triglyceride

    Time frame: 4 weeks

    Absolute change of % hepatic triglyceride (4 week value - 0 week value)

  11. Matsuda Insulin Sensitivity Index (ISI)

    Time frame: 4 week

    Absolute change of Matsuda ISI (4 week value - 0 week value). The Matsuda Index is a ratio of glucose and insulin levels during oral glucose tolerance test. It is calculated using fasting and mean glucose and insulin measurements, but the units of these measurements cancel out in the formula. A Matsuda value less than 2.5 may indicate insulin resistance, thus a lowering of the Matsuda index is a detrimental outcome.

    At baseline the Matsuda index in the participants for which it was assessed ranged from 1.4 to 7.8 (mean = 3.7, standard deviation = 1.6).

  12. Postprandial de Novo Lipogenesis

    Time frame: 4 weeks

    Absolute change of 8-hour area under the curve (AUC) percentage fractional rate postprandial de novo lipogenesis DNL (4 week value - 0 week value)

  13. M Value During Hyperinsulinemic Euglycemic Clamp

    Time frame: 4 weeks

    Absolute change of M value (glucose infusion rate during final 30 minute steady state)/ fat free body mass (kg) (4 week value - 0 week value)

Secondary outcomes

  1. Fasting Triglyceride

    Time frame: 4 weeks

    Absolute change of plasma fasting triglyceride concentration (4 week value - 0 week value)

  2. 3-(3'-Hydroxy-4'-Methoxyphenyl)Hydracrylic

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic (4 week value - 0 week value)

  3. Hesperetin-3'-O-glucuronide

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary hesperetin-3'-O-glucuronide (4 week value - 0 week value)Urine concentration hesperetin-3'-O-glucuronide

  4. Hesperetin-3',7-0-diglucuronide

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary hesperetin-3',7-0-diglucuronide (4 week value - 0 week value)

  5. p-Hydroxyhippuric Acid

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary p-Hydroxyhippuric acid (4 week value - 0 week value)

  6. 3-(4'-Methoxyphenyl)Propionic Acid-3'-O-glucuronide

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary 3-(4'-methoxyphenyl)propionic acid-3'-O-glucuronide (4 week value - 0 week value)

  7. Hesperetin-7-O-glucuronide

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary hesperetin-7-O-glucuronide (4 week value - 0 week value)

  8. Naringin-7-O-glucuronide

    Time frame: 4 weeks

    Absolute change of total 24-hour urinary naringen-7-O-glucuronide (4 week value - 0 week value)

  9. Oral Glucose Tolerance Test (OGTT) Glucose 3-hour Area Under the Curve (AUC)

    Time frame: 4 week

    Absolute change in OGTT 3-hour AUC glucose concentration (4-week value - 0-week value)

  10. Oral Glucose Tolerance Test (OGTT) Insulin 3-hour Area Under the Curve

    Time frame: 4 week

    Absolute change in OGTT 3-hour AUC insulin concentration (4-week value - 0-week value)

  11. Fasting de Novo Lipogenesis

    Time frame: 4 weeks

    Absolute change of fasting percentage fractional rate fasting de novo lipogenesis DNL (4 week value - 0 week value)

Other outcomes

  1. Fasting Insulin

    Time frame: 4 week

    Absolute change serum insulin concentration (4-week value - 0-week value)

  2. Fasting Glucose

    Time frame: glucose

    Absolute change in fasting plasma glucose concentration (4-week value - 0-week value)

  3. Body Weight

    Time frame: 4 weeks

    Change in body weight (4-week value - 0-week value)

  4. Systolic Blood Pressure

    Time frame: 4 weeks

    Change in systolic blood pressure (4-week value - 0-week value)

  5. Diastolic Blood Pressure

    Time frame: 4 weeks

    Change in diastolic blood pressure (4-week value minus 0-week value)

  6. Body Fat

    Time frame: 4 weeks

    %body fat

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • Touro University, California

Registry information

Official study title

The Effects of Orange Juice Compared With Sugar-sweetened Beverage on Risk Factors and Metabolic Processes Associated With the Development of Cardiovascular Disease and Type 2 Diabetes

Acronym: OASIS

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
May 17, 2018
Registry last updated
Nov 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.